4th Quarter - Report

ERVIN GRAVES STRATEGY GROUP, LLC for EMERGENT BIOSOLUTIONS INC.

Period 4th Quarter 2022 Filed Jan 18, 2023 Signed by John Thomas Graves Jr.

Official filing
Firm
ERVIN GRAVES STRATEGY GROUP, LLC
Client
EMERGENT BIOSOLUTIONS INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone; HR 2617 - Consolidated Appropriations Act, 2023 (Omnibus); HR 1437 - Further Continuing Appropriations and Extensions Act; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; Issues related to the development, manufacture, and distribution of coronavirus vaccines

LobbyistCovered position, as disclosed
JAMES L ERVIN —

Contacted: SENATE; Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1437 (117th), H.R. 2617 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.